Načítá se...
Contemporary use of P2Y(12) inhibitors in patients with ST-segment elevation myocardial infarction referred to primary percutaneous coronary interventions in Poland: Data from ORPKI national registry
According to guidelines, it is recommended to give P2Y(12) inhibitors (preferably ticagrelor or prasugrel) at the time of first medical contact in patients with STEMI. However, in real life antiplatelet treatment strategies are different among countries. We analyzed data on antiplatelet treatment in...
Uloženo v:
| Vydáno v: | J Thromb Thrombolysis |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer US
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5756271/ https://ncbi.nlm.nih.gov/pubmed/29075924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-017-1579-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|